| abstract |
Disclosed herein are methods of treating a disorder in a patient by administering immune evading cells. In some embodiments, the patient receives more than one administration of such cells. In some embodiments, the cells disclosed herein have reduced levels or activities of MHC I and/or MHC II human leukocyte antigens. In some embodiments, the cells are derived from primary T cells or pluripotent stem cells that evade immune recognition. In some embodiments, the cells comprise a chimeric antigen receptor. |